ACADIA Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: ACADHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ACADIA Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, ACADIA Pharmaceuticals generated $100.8 million of operating cash flow and spent $5.1 million on capital expenditures. That left free cash flow of $95.7 million, a free-cash-flow margin of 31.1% of revenue. Free cash flow was up 50.3% from the prior year's $63.7 million.
Summary generated from market data by MetaCap's automated system. Methodology
ACADIA Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 31.50M | 3.64M | 273.57M | 71.78M | 26.67M | 18.99M | 143.74M | 32.77M | 33.39M | 16.55M | 45.80M | -65.18M |
| Net Income growth (YoY) | +18.13% | -80.84% | +90.32% | +119.07% | -20.14% | +14.69% | +213.87% | — | +2897.22% | — | — | — |
| Depreciation & Amortization | 434.00K | 271.00K | 202.00K | 227.00K | 213.00K | 229.00K | 226.00K | 226.00K | 226.00K | 242.00K | 272.00K | 359.00K |
| Stock-Based Compensation | 16.94M | 14.70M | 13.23M | 13.18M | 14.34M | 11.38M | 10.45M | 26.16M | 15.69M | 14.75M | 18.02M | 18.54M |
| Change in Working Capital | 23.97M | -19.00M | -16.95M | -20.81M | 4.00M | -14.23M | -5.11M | 6.43M | -34.51M | -15.17M | -12.81M | -25.19M |
| Operating Cash Flow | 100.78M | 33.98M | -48.73M | 74.29M | 63.96M | 20.32M | 40.38M | 63.25M | 25.01M | 29.08M | 85.39M | -58.95M |
| Capital Expenditures | -5.09M | -5.21M | -4.00M | -388.00K | -297.00K | 0 | -453.00K | -70.00K | — | — | 0 | — |
| Investing Cash Flow | -8.53M | 66.28M | -55.87M | -79.35M | -43.29M | -124.05M | 122.15M | -82.46M | -56.19M | -14.04M | -347.00K | 34.11M |
| Financing Cash Flow | 10.49M | 4.23M | 22.67M | 9.42M | 15.96M | 1.84M | 1.97M | 268.00K | 3.56M | 1.04M | 5.43M | 12.75M |
| Net Change in Cash | 102.77M | 104.52M | -81.93M | 4.36M | 36.64M | -101.89M | 164.44M | -18.98M | -27.61M | 16.09M | 90.46M | -12.10M |
| Free Cash Flow | 95.69M | 28.77M | -52.74M | 73.90M | 63.66M | 20.32M | 39.93M | 63.18M | 25.01M | 29.08M | 85.39M | -58.95M |
This table shows 12 quarterly periods of ACADIA Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ACAD's reporting calendar. What is a cash flow statement?